ResearchAltered fibroblast proteoglycan production in COPD
O. Hallgren,Kristian Nihlberg,M. Dahlbäck,L. Bjermer,L. Eriksson,J. Erjefält,C. Löfdahl,G. Westergren-Thorsson
Abstract:Background: Airway remodeling in COPD includes reorganization of the extracellular matrix. Proteoglycans play a crucial role in this process as regulators of the integrity of the extracellular matrix. Altered proteoglycan immunostaining has been demonstrated in COPD lungs and this has been suggested to contribute to the pathogenesis. The major cell type responsible for production and maintenance of ECM constituents, such as proteoglycans, are fibroblasts. Interestingly, it has been proposed that central airways and alveolar lung parenchyma contain distinct fibroblast populations. This study explores the hypothesis that altered depositions of proteoglycans in COPD lungs, and in particular versican and perlecan, is a result of dysregulated fibroblast proteoglycan production. Methods: Proliferation, proteoglycan production and the response to TGF-β1 were examined in vitro in centrally and distally derived fibroblasts isolated from COPD patients (GOLD stage IV) and from control subjects. Results: Phenotypically different fibroblast populations were identified in central airways and in the lung parenchyma. Versican production was higher in distal fibroblasts from COPD patients than from control subjects (p < 0.01). In addition, perlecan production was lower in centrally derived fibroblasts from COPD patients than from control subjects (p < 0.01). TGF-β1 triggered similar increases in proteoglycan production in distally derived fibroblasts from COPD patients and control subjects. In contrast, centrally derived fibroblasts from COPD patients were less responsive to TGFβ1 than those from control subjects. Conclusions: The results show that fibroblasts from COPD patients have alterations in proteoglycan production that may contribute to disease development. Distally derived fibroblasts from COPD patients have enhanced production of versican that may have a negative influence on the elastic recoil. In addition, a lower perlecan production in centrally derived fibroblasts from COPD patients may indicate alterations in bronchial basement membrane integrity in severe COPD. Background Chronic obstructive pulmonary disease (COPD) is a progressive disease characterized by a reduction in respiratory airflow that is not possible to normalize [1]. The reduced airflow is caused by tissue remodeling, including reorganization of the extracellular matrix (ECM). In bronchi, epithelial dysregulation results in impaired mucocilliary clearance, over-production of mucus, and squamous cell metaplasia. In parallel with this, subepithelial fibrosis is often observed in bronchi and bronchioles. Degradation of alveolar walls (emphysema) is a hallmark of COPD, which limits the area of air-blood exchange and the elastic recoil [2]. Other structural changes in COPD, such as thickening of the airway wall and reticular basement membrane, have been implicated as factors that contribute to reduction in airflow [3,4]. Interestingly, in terms of the turnover of ECM, opposing pathological processes occur in the COPD lung as the ECM is degraded in alveoli and there is excessive deposition of ECM (fibrosis) in bronchi and in bronchioles [5]. The major cell type responsible for production and maintenance of the ECM are fibroblasts. Recently, it was suggested that central airways and alveolar lung parenchyma contain distinct fibroblast populations [6,7]. Fibroblasts * Correspondence: oskar.hallgren@med.lu.se 1 Department of Experimental Medical Science, BMC D12 Lund, Lund University, Sweden Full list of author information is available at the end of the article BioMed Central © 2010 Hallgren et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Hallgren et al. Respiratory Research 2010, 11:55 http://respiratory-research.com/content/11/1/55 Page 2 of 11 from these anatomical sites were found to have different morphology, proliferation, and ECM production. This distinction is important to consider in COPD, as the ECM turnover is different in bronchi and alveoli. A key family of molecules for ECM integrity is the proteoglycans. The production of proteoglycans and other ECM molecules have been reported to be modulated by the profibrotic signal molecule TGF-β [8,9]. Proteoglycans have been shown to be differentially expressed in COPD lungs [10,11]. For example, enhanced alveolar immunostaining of the large proteoglycan versican has been reported in COPD patients [10]. As versican may inhibit the assembly of elastic fibers, it may have a negative effect on the elastic recoil and thereby possibly contribute to the pathogenic development of COPD. Moreover, perlecan, a heparan sulphate proteoglycan, is crucial for basement membrane integrity and reduced perlecan immunostaining has been demonstrated in the lungs of COPD patients [11]. In this study, we hypothesized that altered levels of proteoglycans in COPD lungs may be dependent on dysregulated proteoglycan production in fibroblasts and hence that there are alterations in fibroblast phenotypes in COPD patients compared to control subjects. In particular, we wanted to determine whether enhanced alveolar versican deposition is due to higher versican production by distal fibroblasts. We also wanted to examine whether perlecan production was altered in centrally derived fibroblasts. Thus, we isolated centrally and distally derived fibroblasts from lung explants from COPD patients and from biopsies from healthy control subjects in order to assess proteoglycan production, proliferative potential, and responsiveness to TGF-β1 in vitro. Methods Patients Patients (n = 8) suffering from very severe COPD (GOLD stage IV) who were undergoing lung transplantation at Lund University Hospital were included in the study. The patients had quitted smoking at least 6 months before the lung transplantation. Non-smokers (n = 12) with no clinical history of asthma, (reversibility < 12% after administration of the β2-agonist salbutamol (400 μg) and did not respond to methacholine test doses (< 2,000 μg)), or other lung diseases were included as control subjects. This study was approved by the Swedish Research Ethical Committee in Lund (FEK 91/2006 and FEK 213/2005). Isolation of cells Fibroblasts were isolated from explants from COPD patients and from bronchial and transbronchial biopsies from control subjects as previously described [12]. Briefly, biopsies from control subjects were immediately after sampling transferred to cell culture medium (DMEM supplemented with 10% FBS, Gentamicin, PEST, and Ampotericin B (all from Gibco BRL, Paisley, UK)). Specimens from the lung explants were dissected directly after removal from the COPD patients and were immediately transferred to cell culture medium. Bronchial tissue was collected from the luminal side from the same localisation as where bronchial biopsies were taken and were chopped into small pieces. Alveolar parenchymal specimens from explants were collected 2-3 cm from the pleura in the lower lobes, i.e. from the same location as where transbronchial biopsies were taken. Vessels and small airways were removed from the peripheral lung tissues and the remaining tissues were chopped into small pieces. After rinsing, bronchial and parenchymal pieces from explants and biopsies were allowed to adhere to the plastic of cell culture flasks for 4 h and were then kept in cell culture medium in 37°C cell incubators until outgrowth of fibroblasts were observed. Bronchial and parenchymal fibroblasts were then referred to as central and distal fibroblasts, respectively. Experiments were performed at passages 3-6. The cell cultures were continuously stained to verify the mesenchymal identity and to estimate the purity. In the few cases when the cellular staining was less clear then the cell morphology was verified to be representative for the culture as a whole. Proliferation assay Proliferation was determined as previously described [13]. Briefly, cells were plated and fixed after 6, 24, 48, h. Cells were stained with Crystal Violet and cell numbers were quantified indirectly by absorbance at 595 nm on a spectrophotometer plate reader (ELX800; Biotek Instruments, Winooski, VT,). Proliferation was defined as absorbance at 48 h divided by the absorbance after 6 h. With this method the amount of adsorbed dye has been shown to be proportional to the cell number recorded on a Coulter counter [14]. Immunohistochemistry Staining of fibroblasts Fibroblasts (7000/well) grown overnight were fixed in 4% paraformaldehyde for 15 minutes. Thereafter unspecific binding sites were blocked by 2% BSA-TBS containing 5% goat serum (Vector laboratories, Burlingame, CA) and 0,1% Triton X for 30 minutes. Cells were incubated with primary antibodies: monoclonal mouse antibody against Prolyl 4-Hydroxylase (Acris antibodies, Hiddenhausen, Germany), monoclonal mouse IgM antibody against Vimentin (Santa Cruz Biotechnology, Santa Cruz, CA), monoclonal mouse IgG2a antibody against α-SMA (Dako, Glostrup, Denmark), monoclonal IgG and antibody against SM22-alpha (Abcam, Cambridge, UK), and with secondary antibodies: Alexafluor 488-conjugated goat anti-mouse antibody and Alexafluor 555-conjugated Hallgren et al. Respiratory Research 2010, 11:55 http://respiratory-research.com/content/11/1/55 Page 3 of 11 goat anti-mouse antibody (both from Molecular Probes Invitrogen, Eugene, OR). The DNA-binding molecule DAPI (Molecular Probes Invitrogen, Eugene, OR) was used to stain cell nuclei before final mounting (Dako fluorescence mounting medium, Dako, Glostrup, Denmark). Cells were photographed using a TE2000-E fluorescence microscope (Nikon, Tokyo, Japan) equipped with a DXM1200C camera (Nikon, Tokyo, Japan). Tissue staining of proteoglycans In short, tissue, from same locations as where pie